Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)Naoya Yamazaki, Kenji Yokota, Manabu Fujimoto et al.|Cancer Chemotherapy and Pharmacology|2017Cited by 89